All Drug Discovery Processes articles – Page 19
-
NewsKidney organoids reveal hidden toxicities in AAV gene therapy
Stem cell-derived kidney organoids have revealed hidden toxicities in adeno-associated virus (AAV) gene therapy delivery – offering a powerful new way to improve the safety of future treatments.
-
NewsPlanaria flatworms provide new way to study schizophrenia drugs
A new study has shown that small pond worms, called planaria, respond to psychiatric drugs like rodents – offering a promising new way of studying mental health conditions such as schizophrenia and addiction.
-
NewsStriosomes may hold the key to better treatments for mental disorders
Scientists have developed a new computational model that reveals how the striosomal compartment of the brain’s striatum influences decision-making – which could lead to improved therapies for psychiatric disorders.
-
ArticleWhat if drug discovery took months, not decades?
Drug discovery is slow, costly and often unsuccessful. DTR hears how GATC Health is applying AI and multiomics to make the process faster, more precise and less reliant on trial and error.
-
NewsNew CRISPR breakthrough could transform sickle cell treatment
Researchers at UNSW Sydney have unveiled a next-generation CRISPR tool that could lead to safer treatments for genetic disorders, including Sickle Cell.
-
ArticleHow to select the optimal bispecific antibody format for therapeutic success
Choosing the right bispecific antibody format can make or break your therapy’s success. This article explores how format impacts function, manufacturability and development strategy - helping you make the best choice from the start.
-
NewsHow to select the optimal bispecific antibody format for therapeutic success
Discover the key scientific, strategic and manufacturing factors that could decide whether your bsAb succeeds in the clinic or stalls in development.
-
ArticleChallenges in developing robust potency assays for ADCs
Developing robust potency assays for Antibody-Drug Conjugates (ADCs) is crucial for ensuring their clinical success, but designing assays that meet both technical and regulatory standards is challenging. Here, Abzena’s CSO Campbell Bunce explores the complexities of assay development and the importance of ensuring accuracy, consistency and regulatory alignment for ADCs ...
-
NewsFDA-approved asthma drug may protect against food allergy reactions
An existing asthma drug has been shown to almost completely prevent life-threatening allergic reactions to food in mice, after researchers found a previously unknown genetic pathway linked to anaphylaxis.
-
NewsEvenamide targets multiple symptoms in schizophrenia models
New preclinical research suggests that evenamide – a glutamate modulator – targets hippocampal hyperexcitability, potentially addressing positive, negative and cognitive symptoms of schizophrenia.
-
ArticleBeyond the hype: a veteran’s honest assessment of AI in drug discovery - Part 1
An interview with Thibault Géoui reveals why this technology wave might finally break through pharma’s productivity crisis – and why it will take longer than the optimists claim.
-
ArticleLupus reimagined: targeting the cause, not just the symptoms
Engineered cell therapies are offering a potential new way to treat lupus – not by suppressing symptoms, but by reprogramming the immune system itself. For the first time, lasting remission looks like a real possibility.
-
NewsNew PCAI compound targets aromatase inhibitor-resistant breast cancer
Researchers at Florida A&M University have identified a new compound – NSL-YHJ-2-27 – that disrupts key survival pathways in aromatase inhibitor-resistant breast cancer cells – offering a potential new treatment for hard-to-treat cases.
-
NewsKidney tumour organoids offer new drug testing platform
Scientists in China have used 3D bioprinting to grow kidney tumours from patients’ own cells, creating realistic models that could speed up development of personalised treatments.
-
NewsLithium deficiency identified as key Alzheimer’s trigger
New research from Harvard Medical School shows that natural lithium deficiency in the brain may be a key early factor driving Alzheimer’s disease – which allow for the development of new approaches to preventing and reversing cognitive decline.
-
News
Targeted microglia transplant reverses signs of rare brain disorder
Stanford Medicine researchers have developed a targeted brain cell transplant that replaced most diseased microglia in mice with Sandhoff disease – extending their lifespan and reversing symptoms
-
News
New patent for traumatic brain injury drug announced
Drug discovery company, TauGen, has filed a US patent application for a new series of drug candidates targeting endoplasmic reticulum (ER) stress – a key factor in secondary brain injury following traumatic brain injury (TBI).
-
ArticleFrom injections to pills: oral peptides set to transform drug development
Oral peptide-based drugs are set to revolutionise the pharmaceutical industry, overcoming the long-standing challenge of poor bioavailability. Santosh Kulkarni reveals how new breakthroughs in drug discovery and delivery offer the potential for more convenient, effective treatments for a range of conditions – without the need for injections.
-
ArticleHow AI is quietly changing drug manufacturability
AI is moving beyond drug design to answer a critical question: can a promising compound actually be manufactured at scale? By predicting synthetic feasibility early, machine learning tools are helping drug developers avoid costly failures, streamline R&D and design molecules that are both effective and practical to produce.
-
NewsTurning up the heat: simple temperature change makes versatile vaccine nanoparticles
University of Chicago researchers have developed a scalable nanoparticle platform that self-assembles with just a temperature change – enabling safe, solvent-free delivery of proteins and RNA for vaccines and therapies.